Accordingly, the CDK4/6 inhibitors named palbociclib, ribociclib and abemaciclib have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the management of ER-positive and HER2-negative advanced BC in combination with endocrine therapy [22]. This evidence concerns the gene CDK4 and breast cancer.